NCT00367952View on ClinicalTrials.gov

A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

HIV Infection

Interventions

DRUG

apricitabine

800mg apricitabine twice daily orally for 96 weeks

Trial Locations (1)

3121

Avexa (co-ordinating sites in Australia and Argentina), Melbourne

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Avexa

INDUSTRY

NCT00367952 - A Long Term, Safety Study of Apricitabine in HIV-infected Subjects | Biotech Hunter | Biotech Hunter